medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Cellular immunotherapy in multiple myeloma

Korean Journal of Internal Medicine 2019년 34권 5호 p.954 ~ 965
 ( Vo Manh-Cuong ) - Chonnam National University Hwasun Hospital Department of Hematology-Oncology

 ( Lakshmi Thangaraj Jaya ) - Chonnam National University Hwasun Hospital Research Center for Cancer Immunotherapy
 ( Jung Sung-Hoon ) - Chonnam National University Hwasun Hospital Research Center for Cancer Immunotherapy
 ( Cho Duck ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Laboratory Medicine and Genetics
 ( Park Hye-Seong ) - Chonnam National University Hwasun Hospital Research Center for Cancer Immunotherapy
 ( Chu Tan-Huy ) - Chonnam National University Hwasun Hospital Research Center for Cancer Immunotherapy
 ( Lee Hyun-Ju ) - Kongju National University College of Industrial Science
 ( Kim Hyeoung-Joon ) - Chonnam National University Hwasun Hospital Department of Hematology-Oncology
 ( Kim Sang-Ki ) - Kongju National University College of Industrial Science
 ( Lee Je-Jung ) - Chonnam National University Hwasun Hospital Department of Hematology-Oncology

Abstract


In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects.

키워드

Multiple myeloma; Cellular immunotherapy; Immunomodulatory drug; Dendritic cells; Killer cells, natural; Engineered effector T cell
원문 및 링크아웃 정보
  
등재저널 정보
SCI(E)
MEDLINE
KCI
KoreaMed
KAMS